HKG:6996

Antengene's CFO Steps Down; Chief Business Officer Named

Antengene's (HKG:6996) Chief Financial Officer Donald Andrew Lung resigned effective Aug. 1 to pursue other career opportunities, according to a Friday Hong Kong bourse filing.Separately, the cancer therapy developer named Rui Guo as its chief business officer with effect from the same day. Guo has been a part of the Company since 2017.

Antengene Receives $60 Million Milestone in UCB Licensing Deal

Antengene (HKG:6996) received the $60 million upfront payment from UCB under their exclusive licensing agreement for ATG-201, according to a Hong Kong bourse filing Monday.The licensing agreement, announced in March, grants UCB exclusive global rights to develop and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager antibody.The company said the payment strengthens its cash position and will support the advancement of its drug pipeline.

Soochow Securities Starts Antengene at Buy With HK$10.60 Price Target

Antengene Licenses ATG-106 to K2 Therapeutics in Potential $981 Million Deal

Antengene (HKG:6996) granted K2 Therapeutics rights outside Greater China to develop and commercialize ATG-106, a preclinical CDH6 x CD3 bispecific T-cell engager for solid tumors, according to a Monday Hong Kong bourse filing.The agreement entitles Antengene to about $20 million in upfront and near-term consideration, consisting of cash and a minority equity stake in a K2 subsidiary.The company is also eligible to receive up to $960.5 million in development, regulatory, and sales milestone payments, plus royalties on future net sales.Separately, K2 obtained an option to license an undisclosed preclinical bispecific T-cell engager candidate from Antengene.If exercised, the arrangement would provide Antengene with the upfront payment and near-term payments, up to $960.5 million in milestone payments, and royalties on future sales.

Antengene Secures China IND Approval for Autoimmune Disease Drug

Antengene (HKG:6996) said China's National Medical Products Administration has approved an Investigational New Drug (IND) application for a Phase I study of ATG-201, according to a voluntary filing on the Hong Kong Stock Exchange on Wednesday.The ATG-201 is a CD19/CD3 bispecific T-cell engager antibody targeting B-cell-related autoimmune diseases.The company plans to promptly initiate the Phase I trial in China while concurrently preparing for clinical development in Australia.Antengene has secured 33 IND approvals in the U.S. and Asia, 10 NDA approvals across Asia-Pacific markets, and its lead asset XPOVIO (selinexor) is approved in 10 markets and included in five national insurance schemes.The Group cautions that it cannot guarantee ATG-201 will be successfully developed and marketed.

Antengene Secures Chinese Regulatory Nod for Phase 3 Trial

Antengene (HKG:6996) said the Center for Drug Evaluation of China's National Medical Products Administration endorsed a phase 3 study of ATG-022 in advanced gastric or gastroesophageal junction adenocarcinoma, according to a Thursday filing with the Hong Kong bourse.The trial, called CLINCH-3, is expected to be initiated in China first and is planned as a multi-regional clinical trial.The study is intended to support a future marketing approval application for ATG-022 as a monotherapy.

Antengene Appoints Chief Scientific Officer

Antengene (HKG:6996) appointed Bing Hou as chief scientific officer, according to a Wednesday Hong Kong bourse filing.Hou will oversee the company's drug discovery, translational medicine, and chemistry, manufacturing and controls functions, reporting directly to Chairman and Chief Executive Officer Jay Mei.The company said Hou previously served as vice president and head of discovery science and translational medicine.